Rigel Pharmaceuticals reported 8.61 in PE Price to Earnings for its fiscal quarter ending in March of 2025.





Pe Change Date
Amgen 18.6 0.53 Sep/2026
Anika Therapeutics 47.54 27.2 Jun/2024
Arrowhead Research 39.19 0 Jun/2026
AstraZeneca 24.63 0.71 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Daiichi Sankyo 18.6 1.54 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Halozyme Therapeutics 16.12 3.61 Sep/2026
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ligand Pharmaceuticals 68.1 16.21 Sep/2026
Neurocrine Biosciences 83.17 61.07 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Veracyte 29.55 13.22 Sep/2026